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Abstract Purpose: Particulate
contamination due to infusion therapy
carries a potential health risk for
intensive care patients. Meth-
ods: This single-centre, prospective,
randomized controlled trial assessed
the effects of filtration of intravenous
fluids on the reduction of complica-
tions in critically ill children admitted
to a pediatric intensive care unit
(PICU). A total of 807 subjects were
randomly assigned to either a control
(n = 406) or filter group (n = 401),
with the latter receiving in-line fil-
tration. The primary endpoint was
reduction in the rate of overall com-
plications, which included the
occurrence of systemic inflammatory
response syndrome (SIRS), sepsis,
organ failure (circulation, lung, liver,
kidney) and thrombosis. Secondary
objectives were a reduction in the
length of stay on the PICU and
overall hospital stay. Duration of
mechanical ventilation and mortality
were also analyzed. Find-
ings: Analysis demonstrated a
significant reduction in the overall
complication rate (n = 166 [40.9 %]
vs. n = 124 [30.9 %]; P = 0.003) for
the filter group. In particular, the
incidence of SIRS was significantly
lower (n = 123 [30.3 %] vs. n = 90
[22.4 %]; P = 0.01). Moreover the
length of stay on PICU (3.89 [95 %
confidence interval 2.97-4.82] vs.
2.98 [2.33-3.64]; P = 0.025) and
duration of mechanical ventilation
(14.0 [5.6-22.4] vs. 11.0 [7.1-14.9]
h; P = 0.028) were significantly
reduced. Conclusion: In-line filtra-
tion is able to avert severe
complications in critically ill patients.
The overall complication rate during
the PICU stay among the filter group
was significantly reduced. In-line fil-
tration was effective in reducing the
occurrence of SIRS. We therefore
conclude that in-line filtration
improves the safety of intensive care
therapy and represents a preventive
strategy that results in a significant
reduction of the length of stay in the
PICU and duration of mechanical
ventilation (ClinicalTrials.gov num-
ber: NCT00209768).
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Introduction
The intravenous administration of fluids and drugs is
essential in the management of critically ill patients. The
contamination of infusion solutions by particles is a
widely unknown and underestimated side effect of intra-
venous therapy [1, 2]. Particulate contamination is due to
drug incompatibility reactions or their incomplete recon-
stitution during the preparation process [3]. Various
studies have demonstrated the contamination of infusion
solutions with glass particles from opening glass
ampoules, particles from rubber stoppers or conglomer-
ates of the parenteral nutrition components [4, 5].
Particles have also been shown to be inherent to generic
drug formulation [2]. In an intensive care setting the
particle burden may rise up to one million infused parti-
cles per day, increasing with the complexity and quantity
of the administered infusions [6, 7]. Acknowledging the
risks associated with such contamination, it is important
to optimize infusion therapy in order to minimize medi-
cation errors and particle load. Therefore, standard
operational procedures for the infusion set-up, databases
for the prevention of drug incompatibilities and training
of medical staff can be helpful tools to improve patient
safety [3, 8, 9]. In addition, in-line filtration has been
shown to almost completely prevent particulate infusion
[4]. Two intravenous fluid filters are currently in wide-
spread use: 0.2-lm filters for crystalline solutions and 1.2-
lm filters for lipid-containing admixtures. Positively
charged 0.2-lm filters are able to retain particles, air and
micro-organisms and endotoxins [10].
Post-mortem examinations of adults suffering from
acute respiratory distress syndrome (ARDS) [7] and
children with underlying disease [11] have revealed that
infusion therapy can lead to particle-induced mechanical
blockage of vessels and the generation of pulmonary
foreign body granulomata. Particles harm the pulmonary
endothelium either directly or through activation of
complement, platelets and/or neutrophils, leading to the
formation of occlusive microthrombi [7, 12]. In vitro
studies with endothelial cells and macrophages have also
demonstrated particle-induced modulation of immune
response [5]. The effect of particle infusions is aggravated
in situations of disturbed microcirculation, such as
ischemia and reperfusion injury: after cardioplegia, par-
ticles in cardioplegia solutions lead to impaired coronary
artery flow, alterations in endothelium and increased
leukocyte adhesion in humans as well as in animals [1]. In
an experimental rat liver transplantation model, particles
in the preservation solution were found to disturb the
microcirculation and aggravate post-ischemic inflamma-
tion [13]. In a hamster skinfold chamber model, following
ischemia, intravenous infusion of particle-contaminated
solutions reduced functional capillary density by almost
50 %, compared to post-ischemic values before particle
injection [14, 15]. However, filtration of solutions through
0.2-lm in-line filters prevented the loss of capillaries
completely [15] and attenuated the inflammatory process
[1, 13].
Previous clinical trials of in-line filtration primarily
focused on the retention of micro-organisms, demon-
strating a preventive effect on thrombophlebitis [16]
without any impact on central venous catheter-related
sepsis [17]. To date, no clinical trial has taken account of
the results of experimental studies on particle contami-
nation. However, a clinical effect of particle retentive in-
line filtration would be expected to be most evident
in situations of altered microcirculatory homoeostasis or
immune response. Intensive care patients who experi-
enced trauma, major surgery or systemic inflammation
suffer from conditions that affect the microcirculation of
tissues and vital organs [18].
This single-centre, prospective, randomized, con-
trolled trial in critically ill children was conducted to
evaluate the impact of in-line filtration on severe com-
plications, such as systemic inflammatory response




This was a single-centre, prospective, randomized, con-
trolled trial conducted between February 2005 and
September 2008 in an interdisciplinary pediatric intensive
care unit (PICU) of a tertiary German hospital. Approval
of the study protocol was obtained from the local ethics
committee. Funding was primarily provided by a research
grant of Hannover Medical School and partially by an
unrestricted grant from Pall, Dreieich, Germany and
B. Braun Melsungen, Germany. Both companies supplied
in-line filters. An open label study design characterized by
visible in-line filters was necessary to ensure maximum
safety in drug administration and to allow nurses to
monitor the in-line filters for imminent blockage. Any
adverse events relating to in-line filtration were recorded.
Patient enrolment and randomization
All patients younger than 18 years of age who were
admitted to the PICU during the study period were eli-
gible for enrollment (n = 2,542). Subjects expected to die
within 48 h of admission, such as those under cardio-
pulmonary resuscitation, and patients already recruited
for other trials or without any intravenous therapy were
excluded (Fig. 1). Written informed consent was obtained
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for each child from their legal guardians on admission. A
total of 1,147 patients met the inclusion criteria. These
patients were randomly allocated to either the control or
filter group based on a computer-generated simple unre-
stricted randomization list. Discharge within 6 h after
admission was defined as an exclusion criterion. Fourteen
patients (8 control, 6 filter group) were excluded during
final validation due to missing relevant clinical data in
their charts. The final analysis included 807 patients (343
female, 464 male) (Fig. 1).
Infusion management and in-line filtration
Prior to this study, the infusion regimen was standardized
for patients in both groups. A computer database contain-
ing information on compatibilities of drugs (KiK 3.0;
ODATA, Rastede, Germany) was used to prevent incom-
patibilities [3]. Medications were prepared according to the
manufacturer’s instructions. Parenteral nutrition and
certain drugs (special antibiotics, antiviral drugs, antimy-
cotics, chemotherapy) were supplied by a centralized
intravenous additive service (CIVA) to guarantee chemical
stability and aseptic standards. The filter group received in-
line filtration throughout the period of infusion therapy,
and all fluids except blood, plasma proteins or fresh frozen
plasma were administered via in-line filters. The appro-
priate filters (1.2-lm pore size [Intrapur Lipid/Intrapur
Neonat Lipid; B. Braun Corporation, Melsungen, Ger-
many] for infusion of lipid-containing admixtures; 0.2-lm
pore size positively charged filters [ELD96LLCE/
NEO96E; Pall, Dreieich, Germany] for aqueous solutions)
were arranged in the lumen of each central and peripheral
venous catheter (Fig. 1 of the Electronic Supplementary
Material [ESM]). Nurses checked the in-line filters at least
every hour for imminent blockage. Filters were replaced
after 24 h (Intrapur Lipid/Intrapur Neonat Lipid) or 72 h
(ELD96LLCE/NEO96E) of regular use or in case of
blockage. In both groups, the administration sets for lipid-
containing admixtures were changed every 24 h, others
every 72 h as recommended by the Robert Koch Institute
[19]. Nurses and physicians were extensively trained prior
to the study to ensure correct and safe in-line filter handling
and a competent infusion management.
Endpoints
Given the low mortality in PICU, we chose reduction in
the overall complication rate of major events as the pri-
mary endpoint. Major events included the incidence of
SIRS, sepsis, thrombosis, acute liver failure, ARDS and
acute renal and circulatory failure. The occurrence of at
least one of these major events during the PICU stay
accounted for one complication per patient in the calcu-
lation of the overall complication rate. Complications
prior to PICU stay and on admission were not taken into
account. Sepsis and SIRS were defined according to
International Pediatric Sepsis Consensus Conference
(IPSCC) 2005 [20, 21]. All other endpoints were defined
according to accepted pediatric consensus recommenda-
tions [22–25]. Further information is provided in the
Fig. 1 Enrolment of study
subjects. Single asterisk denotes
exclusion criteria: recruitment
for other studies, 18 years of
age or older, no infusion
therapy during the stay in the
pediatric intensive care unit
(PICU). Double asterisk
denotes other reasons for
exclusion: no informed consent
due to foreign language and
ethical reasons. In four patients
allocated to the filter group the
intervention was discontinued.
One patient in the control group
and 8 patients in the filter group
were excluded due to incorrect
allocation. Fourteen patients (8
control, 6 filter group) were
excluded during the final
validation because of
incomplete data in the medical
charts
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ESM. Secondary endpoints were reduction of length of
stay on PICU and overall hospital stay.
Data collection and statistical analysis
Detailed information on data collection is provided in the
ESM. Statistical analysis was performed on an intention-
to-treat basis. In a preceding survey a complication rate of
approximately 40 % was determined. The study was
designed using a chi-square test for equal proportions and
with 80 % power to detect a reduction from 40 to 30 % in
the complication rate for the filter group. At a significance
level of 0.05, based on the previously determined com-
plication rate, this design required 376 subjects to be
enrolled in each group. The study design included an
interim analysis after recruitment of 50 % of the targeted
enrolment to evaluate any possible adverse effects of in-
line filtration. Statistical analysis was performed with the
use of Predictive Analysis Software for Windows, ver. 18
(SPSS, Chicago, IL). Further information on the statistics
is provided in the ESM.
Results
Subjects
The scheduled interim analysis identified no termination
criteria after inclusion of 50 % of the patients eligible for
enrolment, and ethical approval was obtained to continue
recruitment. Ultimately, 807 children were randomly
assigned to either the control group (n = 406) or filter
group (n = 401) and included in the final analysis. Both
groups were well matched, with a similar distribution of
baseline demographic characteristics and underlying dis-
ease categories, and showed no differences in the
Pediatric Index of Mortality II (PIM II) calculations
(Table 1).
For the reporting of adverse events, see ESM.
Primary endpoints
In-line filtration significantly decreased the overall com-
plication rate from 40.9 % (n = 166) in the control group
to 30.9 % (n = 124) in the filter group (P = 0.003),
(Table 2; Fig. 2). The Kaplan–Meier method and log-
rank test were used to analyze the time to first occurrence
of any complication per patient (Fig. 3), and a significant
difference between the control and filter group was found
using the log-rank test (P = 0.003). The median of event-
free time for the control group (7.0 ± 0.2 days) differed
from that for the filter group (10.0 ± 1.9 days). The
incidence of SIRS was significantly reduced in the filter
group compared to that in the control group (22.4
[n = 90] vs. 30.3 % [n = 123], respectively; P = 0.01).
Adjustment to the baseline risk calculation (PIM II) was
performed for overall complication rate and SIRS without
any relevant impact on statistical significance (Table 2).
The Kaplan–Meier analysis revealed a significant differ-
ence in SIRS-free interval for the proportions of patients
of both groups (P = 0.011 by the log-rank test) (Fig. 3).
Although there were reductions in the incidence of sepsis,
ARDS, circulatory failure, thrombosis, acute liver and
acute renal failure in the filter group, these differences did
not reach statistical significance (Table 2; Fig. 2).








Age (years) 5.58 ± 5.59 6.07 ± 6.01 0.23
Weight (kg) 21.8 ± 20.1 23.0 ± 20.7 0.43
Pediatric Index of Mortality
II (PIM II)
4.15 ± 8.76 3.42 ± 9.14 0.25
Sex (n)
Male 230 234 0.72
Female 175 168
Disease category on admission (n)
Cardiology 150 155 0.66
Cardiac bypass 101 102 0.87
Non-bypass 49 53 0.67
Hematology/oncology 24 21 0.76
Elective 13 11 0.84
Non-elective 11 10 1.00
Nephrology 18 26 0.21
Renal transplantation 13 19 0.28
Gastroenterology 37 37 1.00
Liver transplantation 20 19 1.00
Pulmonology 21 18 0.74
Elective 13 11 0.84
Non-elective 8 7 1.00
Pediatric surgery 59 48 0.30
Elective 56 44 0.24
Non-elective 3 4 0.72
Traumatology 34 43 0.28
Elective 0 2 0.25
Non-elective 34 41 0.40
Neurosurgery 26 22 0.66
Elective 23 19 0.63
Non-elective 3 3 1.00
Others 37 31 0.53
Elective 18 16 0.86
Non-elective 19 15 0.60
This table shows the distribution of subjects between the control
and filter groups by demographic characteristics, PIM II and disease
categories on admission. Admissions were subdivided into elective
(previously planned admission) and non-elective admissions. None
of the differences between the two groups were significant
Data are presented as the mean ± standard deviation (SD), or as the
number (n) of patients, where indicated
a P values were calculated using the t test for equality of means,
Pearson’s chi-Square test or Fisher’s exact test, as appropriate
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Secondary endpoints
The length of stay of the filter group in the PICU was
significantly reduced (23 %) compared to that of the
control group (2.98 [95 % confidence interval 2.33-3.64]
vs. 3.89 [2.97-4.82] days, respectively; P = 0.025)
(Table 2). Although statistically not significant, overall
hospital stay was reduced by 1 day in the filter group
verus the control group (15.0 [13.4-16.6] vs. 16.0 [14.2-
17.8] days, respectively; P = 0.19). The duration of
mechanical ventilation was significantly reduced in the
filter group versus that in the control group (11.0 [7.1-
14.9] vs. 14.0 [5.6-22.4] h, respectively; P = 0.028).
There was a statistical trend towards lower mortality in
the filter group (6.7 [n = 27] vs. 4.0 % [n = 16], control
vs. filter group; P = 0.09).
Discussion
In this prospective clinical trial, in-line filtration of
infusion solutions led to a significant decrease in
major complications in critically ill pediatric patients.





P valuea 95 % Confidence
interval
Primary objectives (n)
Complications (overall) 166 124 0.003 0.484-0.865
Adjusted to PIM II 0.011 0.502-0.914
SIRS 123 90 0.011 0.485-0.913
Adjusted to PIM II 0.026 0.500-0.958
Sepsis 27 20 0.313 0.406-1.337
Circulatory failure 60 57 0.593 0.604-1.334
ARDS 35 22 0.082 0.354-1.069
Acute renal failure 16 14 0.736 0.425-1.831
Acute liver failure 9 7 0.631 0.289-2.125
Thrombosis 11 6 0.230 0.200-1.489
Secondary objectives
Mortality (n) 27 16 0.093 0.309-1.100
Length of stay (days)b 3.89 (2.96-4.81) 2.98 (2.33-3.63) 0.025
Duration of mechanical ventilation (h)b 14.0 (5.6-22.4) 11.0 (7.1-14.9) 0.028
Comparison of primary and secondary outcomes between control
and filter group
ARDS Acute respiratory distress syndrome, SIRS systemic inflam-
matory response syndrome
a P values were calculated using Pearson’s Chi-Square test, Fish-
er’s exact test or log-rank test as indicated
b Data are presented as the median with the range given in
parenthesis
Fig. 2 Hazard ratios of primary
objectives for the treatment





significantly reduced in the
filter group. A trend towards a
reduction in acute respiratory
distress syndrome (ARDS) was
evident for the filter group
(P = 0.08). No significant
differences were found for the
incidence of sepsis, circulatory
failure, acute renal failure, acute
liver failure and thrombosis.
Filled rhombi Hazard ratios,
horizontal lines 95 %
confidence intervals
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A significant reduction from 40.9 to 30.9 % in the overall
complication rate of severe events (SIRS, sepsis, circu-
latory failure, ARDS, thrombosis, acute renal failure and
acute liver failure) was demonstrated for the filter group.
Although sample size and power were not calculated to
detect reduction in single complications, the incidence of
SIRS was significantly reduced. Additionally, all other
primary objectives had a lower incidence in the filter
group, but without statistical significance. In-line filtration
significantly decreased both the duration of mechanical
ventilation and the length of stay in the PICU. Consid-
ering the relatively low incidence of mortality in the
PICU compared to an adult cohort, the statistical trend
towards a reduction in mortality rate in the filter group is
especially noteworthy.
This is the first clinical trial involving more than 800
PICU patients to reveal a significant benefit of in-line
filtration on serious complications. However, our results
seem to be in contrast to a recent Cochrane analysis
including 704 neonates and preterm infants of four dif-
ferent trials, which demonstrated no favorable effect of
in-line filtration on morbidity or mortality [26]. Two of
the four studies included in the Cochrane analysis focused
on thrombophlebitis and cannula patency, and only one
study reported on endpoints comparable to those chosen
for our study [27]. In this latter study, the authors dem-
onstrated a significant reduction in the incidence of
typical neonatal complications for in-line filtration, which
is consistent with our data. In the fourth study of van
Hoogen et al. [28], the primary objective was a reduction
of sepsis, which, similar to our results, could not be sig-
nificantly reduced by the use of in-line filters.
In our trial, the majority of severe complications
occurred within the first 3 days following admission to
the PICU, with 40.9 % of patients in the control group
experiencing at least one major complication during this
period. Implementation of in-line filters as early as the
time of admission prevented severe complications and
generated a persistent reduction in the complication rate
(Fig. 3). These protective effects of in-line filtration may
be explained by the preservation of microcirculation in all
organs. The maintenance of microcirculation is particu-
larly crucial in critically ill patients to prevent organ
failure, whereas several frequently coexisting pathologies,
such as inflammation and trauma, compromise the
microcirculation [18]. The early restoration of microcir-
culation shown for inflammatory syndromes such as
sepsis is associated with reduced morbidity and lower
organ failure score [29]. In the pathological state of an
already reduced microcirculatory perfusion, infused par-
ticles may cause additional impairment, leading to a loss
of capillary density, as demonstrated in recent preclinical
studies [14, 15]. Thus, the threshold of organ recovery is
exceeded, and clinical signs of organ dysfunction or
failure arise.
Based on our data, in-line filtration is effective in
preventing SIRS in intensive care patients. SIRS was first
used in adults to describe a nonspecific systemic inflam-
matory process in the absence of infection [21, 30]. SIRS
criteria for adults were incorporated and modified with
age-specific norms for children by the IPSCC [21]. SIRS
in children is manifested by the presence of at least two
of four criteria, one of which must be an abnormal
temperature or leukocyte count: (1) hyperthermia or
hypothermia, (2) tachycardia, (3) tachy- or bradypnoea or
(4) leukocytosis or leukopenia [21]. The occurrence of
SIRS predisposes patients to organ failure and frequently
determines clinical outcomes [30]. Mortality and mor-
bidity of severe non-infectious SIRS does not differ from
those of severe sepsis, as shown in a multicentre trial
involving 3,500 patients admitted to adult intensive care
units [31]. The incidence of SIRS has been found to be
higher than that of sepsis in both adult [31] and pediatric
[32] intensive care patients. SIRS on admission has been
Fig. 3 Kaplan–Meier analysis
for complication-free interval
(a) or SIRS-free interval (b).
Control (blue filled circle) and
filter (red open rhombus) group
(maximum PICU stay 28 days).
Circles and rhombi indicate
censored patients
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shown to determine mortality and the length of stay of
critically ill trauma patients [33]. In a prospective survey
of 3,708 hospitalized adults, patients with SIRS had a
26 % chance of developing sepsis [34]. In another study,
the more SIRS criteria fulfilled by a patient, the more
likely that patient was to develop ARDS, disseminated
intravascular coagulation or acute renal failure or even die
of SIRS [33]. Pathophysiologically, mechanisms of SIRS
and sepsis are similar, but the management of SIRS is
typically non-specific [35]. Only supportive intensive care
management, including fluid resuscitation, mechanical
ventilation, inotropic support combined with the treat-
ment of the initiating insult, might be beneficial [35]. In
this setting of limited therapeutic options, in-line filtration
represents a potent strategy to prevent SIRS and associ-
ated co-morbidities.
Although sample size and power were not calculated
to detect a reduction in ARDS, a statistical trend towards
a reduction was evident for the in-line filtration group.
Consistent with this, a significantly decreased duration
of mechanical ventilation was found, supporting the
hypothesis that the lung as the physiological filter of
intravenous infusion is most vulnerable to particulate
damage. The mechanical obstruction of capillaries in the
lung and other organs by infused particles has been
demonstrated in both clinical and experimental studies [7,
12, 14]; such obstruction may impair coagulation through
the consumption of pro- and anticoagulative proteins and
platelets [7]. In vitro incubation with endothelial cells
and macrophages demonstrated immunomodulating
effects of particles [5]. Similar mechanisms have been
shown for deposits of inhaled particles in the lung, which
initiate a local inflammatory process that expands into a
systemic inflammatory response with an increase in cir-
culating inflammatory factors and activation of immune
cells [36].
We adhered to a standardized infusion regimen, pre-
vented incompatibilities and had access to CIVA and we
still achieved a further reduction in the incidence of
complications by using in-line filtration. The medical
staff received extensive training in the handling of in-line
filters prior to the initiation of our study, followed by
continuous support by the authors during the study per-
iod. This practice enabled the implementation of filters
without any relevant problems and demonstrated the
practicability of the standard infusion arrangement and
filter set-up. Thus, during the entire trial period there
were only an irrelevant number of blocked filters and no
serious adverse events of in-line filtration were noted. To
ensure maximum patient safety in drug administration,
filter membranes were visible in order to control for
imminent blockage or defects. This compulsory open
label study design may be a limitation and a potential
source of bias.
Consistent with results reported in other trials [33], we
have demonstrated a correlation between SIRS and length
of stay in the PICU. Based on our data, one would expect
that applying an in-line filter would also reduce diagnostic
and therapeutic resources and increase turnover on the
PICU. However, economic aspects of in-line filtration
were not an endpoint in our study. As already shown by a
meta-analysis [26], additional costs of in-line filters are
compensated for by the reduced consumption of intrave-
nous administration sets [27, 28] and decreased time for
changing infusion sets [28]. In both of these studies [27,
28], intravenous sets in the control group were changed
daily, while in the in-line filter group (interventional
group) the changing times were extended up to 96 h. Due
to different changing intervals in our study—72 h in both
the control and filter group—these calculations are only
partially applicable. Costs for disposables in our infusion
set-up amounts to an additional expense of approximately
30 Euros for filters plus about 2 min extra work for
equipment set-up. By lengthening the changing time from
72 to 96 h, some of the additional cost could be amor-
tized. In summary, diagnostic and therapeutic resource-
saving effects are likely to outweigh the additional costs
for the filters and, consequently, positive economic effects
can be expected.
In conclusion, the results of our trial demonstrate the
safety and efficacy of in-line filtration in preventing major
complications in patients admitted to the PICU. The
overall complication rate and the incidence of SIRS were
reduced among those patients with in-line filtration,
indicating that filtration is a preventive strategy that can
result in decreased morbidity of critically ill patients,
reduced duration of mechanical ventilation and reduced
length of stay on the PICU. Furthermore, in-line filtration
was shown to improve the safety of infusion therapy.
Further research is necessary to fully elucidate the path-
ophysiological mechanisms underlying our clinical
findings.
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